ERBB2 and breast cancer: The ongoing phase III PATINA trial (NCT02947685) aims to determine whether palbociclib plus anti-HER2 therapy plus endocrine therapy (ET) is superior to HER2-targeted therapy plus ET alone in HR+/HER2+ BC by measuring PFS [138,143].